Interferon‐γ Mediates Anemia but Is Dispensable for Fulminant Toll‐like Receptor 9–Induced Macrophage Activation Syndrome and Hemophagocytosis in Mice
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: Macrophage activation syndrome (MAS) is a devastating cytokine storm syndrome complicating many inflammatory diseases and characterized by fever, pancytopenia, and systemic inflammation. It is clinically similar to hemophagocytic lymphohistiocytosis (HLH), which is caused by viral infection of a host with impaired cellular cytotoxicity. Murine models of MAS and HLH illustrate that interferon‐γ (IFNγ) is the driving stimulus for hemophagocytosis and immunopathology. This study was undertaken to investigate the inflammatory contributors to a murine model of Toll‐like receptor 9 (TLR‐9)–induced fulminant MAS. Methods: Wild‐type, transgenic, and cytokine‐inhibited mice were treated with an IL‐10 receptor blocking antibody and a TLR‐9 agonist, and parameters of MAS were evaluated. Results: Fulminant MAS was characterized by dramatic elevations in IFNγ, IL‐12, and IL‐6 levels. Increased serum IFNγ levels were associated with enhanced IFNγ production within some hepatic cell populations but also with decreased numbers of IFNγ‐positive cells. Surprisingly, IFNγ‐knockout mice developed immunopathology and hemophagocytosis comparable to that seen in wild‐type mice. However, IFNγ‐knockout mice did not become anemic and had greater numbers of splenic erythroid precursors. IL‐12 neutralization phenocopied disease in IFNγ‐knockout mice. Interestingly, type I IFNs contributed to the severity of hypercytokinemia and weight loss, but their absence did not otherwise affect MAS manifestations. Conclusion: These data demonstrate that both fulminant MAS and hemophagocytosis can arise independently of IFNγ, IL‐12, or type I IFNs. They also suggest that IFNγ‐mediated dyserythropoiesis, not hemophagocytosis, is the dominant cause of anemia in fulminant TLR‐9–induced MAS. Thus, our data establish a novel mechanism for the acute anemia of inflammation, but suggest that a variety of triggers can result in hemophagocytic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737 · cited 2×
“The finding of enhanced cytokinemia in fulminant MAS was not surprising given the known suppressive effects of IL-10 on inflammatory cytokine production (27, 28).”
Interleukin‐10: new perspectives on an old cytokine
Mosser, D. M., & Zhang, X. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00706.x · Cited by 1,077
Jordan, M. B., Hildeman, D., Kappler, J., & Marrack, P. (2004) · Blood · doi:10.1182/blood-2003-10-3413 · Cited by 712
Repeated TLR9 stimulation results in macrophage activation syndrome–like disease in mice
Behrens, E. M., Canna, S. W., Slade, K., Rao, S., Kreiger, P. A., Paessler, M., Kambayashi, T., & Koretzky, G. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43157 · Cited by 392 · cited 10×
“most aspects of MAS as compared to mice treated with CpG without IL-12 neutralization (Figure 4B & data not shown), completely phenocopying the effects of CpG-alone on IFNγKO mice (16).”
InfluentialSelf-citationShimizu, M., Yokoyama, T., Yamada, K., Kaneda, H., Wada, H., Wada, T., Toma, T., Ohta, K., Kasahara, Y., & Yachie, A. (2010) · Rheumatology · doi:10.1093/rheumatology/keq133 · Cited by 255 · cited 1×
“Serum cytokines in active MAS demonstrated elevation of a number of inflammatory pathways with heterogeneity likely reflecting the triggering effect of the disease of origin (3, 4).”
Perforin is a critical physiologic regulator of T-cell activation
Lykens, J. E., Terrell, C. E., Zoller, E. E., Risma, K., & Jordan, M. B. (2011) · Blood · doi:10.1182/blood-2010-12-324533 · Cited by 150
Cited by
The Immunology of Macrophage Activation Syndrome
Crayne, C. B., Albeituni, S., Nichols, K. E., & Cron, R. Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00119 · Cited by 633
Interleukin‐18: Biological properties and role in disease pathogenesis
Kaplanski, G. (2018) · Immunological Reviews · doi:10.1111/imr.12616 · Cited by 606
Macrophage activation syndrome in the era of biologic therapy
Grom, A. A., Horne, A., & De Benedetti, F. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.179 · Cited by 448
The IL-1 family of cytokines and receptors in rheumatic diseases
Dinarello, C. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0277-8 · Cited by 366
Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy
Griffin, G., Shenoi, S., & Hughes, G. C. (2020) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2020.101515 · Cited by 349
Metadata
- Authors
- Canna, S. W., Wrobel, J., Chu, N., Kreiger, P. A., Paessler, M., & Behrens, E. M.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2013-07
- Volume
- 65
- Issue
- 7
- Pages
- 1764-1775
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1510337463
- Cited by
- 117
- References
- 6
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.